Baidu
map

百时美施贵宝的1-磷酸鞘氨醇受体调节剂ozanimod,获FDA批准治疗复发型多发性硬化症

2020-03-26 MedSci原创 MedSci原创

Ozanimod作为每日一次的口服药物,是目前唯一获批的1-磷酸鞘氨醇受体调节剂。

百时美施贵宝(Bristol Myers Squibb)宣布,FDA批准其新型口服的选择性1-磷酸鞘氨醇受体调节剂Zeposia(ozanimod),用于治疗复发的多发性硬化症(RMS)成人患者,包括临床孤立综合症、复发缓解型和活动继发进行性患者。

该公司指出,由于新型冠状病毒COVID-19的大流行以及当前美国医疗系统面临的巨大压力,ozanimod的商业化将被延迟。

Ozanimod是Bristol Myers Squibb从Celgene公司收购获得,该每日一次的口服药物是目前唯一获批的1-磷酸鞘氨醇受体调节剂。该药物治疗RMS患者前无需进行基因测试,也无需进行基于标签的首次剂量观察。

欧洲药品管理局目前正在审查将该药物用于治疗复发缓解型MS成人患者的市场营销申请,预计将于2020年上半年作出决定。

原始出处:

https://www.firstwordpharma.com/node/1710854?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1983107, encodeId=31d4198310e19, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jul 29 11:45:58 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839785, encodeId=c68e1839e85bf, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Jul 06 23:45:58 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890104, encodeId=823d18901048b, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Mar 09 06:45:58 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764466, encodeId=52fb1e64466a2, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71882, encryptionId=8fe0e188265, topicName=百时美)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b037737594, createdName=ms1467340776200723, createdTime=Sun May 17 02:45:58 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685291, encodeId=c38416852913d, content=<a href='/topic/show?id=03135881224' target=_blank style='color:#2F92EE;'>#施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58812, encryptionId=03135881224, topicName=施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=394828104279, createdName=jktdtl, createdTime=Mon Feb 22 15:45:58 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968815, encodeId=b34c196881590, content=<a href='/topic/show?id=6e2d42514f8' target=_blank style='color:#2F92EE;'>#复发型多发性硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42514, encryptionId=6e2d42514f8, topicName=复发型多发性硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Nov 01 00:45:58 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353493, encodeId=0fbb1353493ed, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71883, encryptionId=43abe1883b6, topicName=百时美施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 28 11:45:58 CST 2020, time=2020-03-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1983107, encodeId=31d4198310e19, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jul 29 11:45:58 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839785, encodeId=c68e1839e85bf, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Jul 06 23:45:58 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890104, encodeId=823d18901048b, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Mar 09 06:45:58 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764466, encodeId=52fb1e64466a2, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71882, encryptionId=8fe0e188265, topicName=百时美)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b037737594, createdName=ms1467340776200723, createdTime=Sun May 17 02:45:58 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685291, encodeId=c38416852913d, content=<a href='/topic/show?id=03135881224' target=_blank style='color:#2F92EE;'>#施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58812, encryptionId=03135881224, topicName=施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=394828104279, createdName=jktdtl, createdTime=Mon Feb 22 15:45:58 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968815, encodeId=b34c196881590, content=<a href='/topic/show?id=6e2d42514f8' target=_blank style='color:#2F92EE;'>#复发型多发性硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42514, encryptionId=6e2d42514f8, topicName=复发型多发性硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Nov 01 00:45:58 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353493, encodeId=0fbb1353493ed, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71883, encryptionId=43abe1883b6, topicName=百时美施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 28 11:45:58 CST 2020, time=2020-03-28, status=1, ipAttribution=)]
    2020-07-06 bugit
  3. [GetPortalCommentsPageByObjectIdResponse(id=1983107, encodeId=31d4198310e19, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jul 29 11:45:58 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839785, encodeId=c68e1839e85bf, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Jul 06 23:45:58 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890104, encodeId=823d18901048b, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Mar 09 06:45:58 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764466, encodeId=52fb1e64466a2, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71882, encryptionId=8fe0e188265, topicName=百时美)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b037737594, createdName=ms1467340776200723, createdTime=Sun May 17 02:45:58 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685291, encodeId=c38416852913d, content=<a href='/topic/show?id=03135881224' target=_blank style='color:#2F92EE;'>#施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58812, encryptionId=03135881224, topicName=施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=394828104279, createdName=jktdtl, createdTime=Mon Feb 22 15:45:58 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968815, encodeId=b34c196881590, content=<a href='/topic/show?id=6e2d42514f8' target=_blank style='color:#2F92EE;'>#复发型多发性硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42514, encryptionId=6e2d42514f8, topicName=复发型多发性硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Nov 01 00:45:58 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353493, encodeId=0fbb1353493ed, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71883, encryptionId=43abe1883b6, topicName=百时美施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 28 11:45:58 CST 2020, time=2020-03-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1983107, encodeId=31d4198310e19, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jul 29 11:45:58 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839785, encodeId=c68e1839e85bf, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Jul 06 23:45:58 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890104, encodeId=823d18901048b, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Mar 09 06:45:58 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764466, encodeId=52fb1e64466a2, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71882, encryptionId=8fe0e188265, topicName=百时美)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b037737594, createdName=ms1467340776200723, createdTime=Sun May 17 02:45:58 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685291, encodeId=c38416852913d, content=<a href='/topic/show?id=03135881224' target=_blank style='color:#2F92EE;'>#施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58812, encryptionId=03135881224, topicName=施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=394828104279, createdName=jktdtl, createdTime=Mon Feb 22 15:45:58 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968815, encodeId=b34c196881590, content=<a href='/topic/show?id=6e2d42514f8' target=_blank style='color:#2F92EE;'>#复发型多发性硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42514, encryptionId=6e2d42514f8, topicName=复发型多发性硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Nov 01 00:45:58 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353493, encodeId=0fbb1353493ed, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71883, encryptionId=43abe1883b6, topicName=百时美施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 28 11:45:58 CST 2020, time=2020-03-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1983107, encodeId=31d4198310e19, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jul 29 11:45:58 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839785, encodeId=c68e1839e85bf, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Jul 06 23:45:58 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890104, encodeId=823d18901048b, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Mar 09 06:45:58 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764466, encodeId=52fb1e64466a2, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71882, encryptionId=8fe0e188265, topicName=百时美)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b037737594, createdName=ms1467340776200723, createdTime=Sun May 17 02:45:58 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685291, encodeId=c38416852913d, content=<a href='/topic/show?id=03135881224' target=_blank style='color:#2F92EE;'>#施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58812, encryptionId=03135881224, topicName=施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=394828104279, createdName=jktdtl, createdTime=Mon Feb 22 15:45:58 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968815, encodeId=b34c196881590, content=<a href='/topic/show?id=6e2d42514f8' target=_blank style='color:#2F92EE;'>#复发型多发性硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42514, encryptionId=6e2d42514f8, topicName=复发型多发性硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Nov 01 00:45:58 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353493, encodeId=0fbb1353493ed, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71883, encryptionId=43abe1883b6, topicName=百时美施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 28 11:45:58 CST 2020, time=2020-03-28, status=1, ipAttribution=)]
    2021-02-22 jktdtl
  6. [GetPortalCommentsPageByObjectIdResponse(id=1983107, encodeId=31d4198310e19, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jul 29 11:45:58 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839785, encodeId=c68e1839e85bf, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Jul 06 23:45:58 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890104, encodeId=823d18901048b, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Mar 09 06:45:58 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764466, encodeId=52fb1e64466a2, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71882, encryptionId=8fe0e188265, topicName=百时美)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b037737594, createdName=ms1467340776200723, createdTime=Sun May 17 02:45:58 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685291, encodeId=c38416852913d, content=<a href='/topic/show?id=03135881224' target=_blank style='color:#2F92EE;'>#施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58812, encryptionId=03135881224, topicName=施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=394828104279, createdName=jktdtl, createdTime=Mon Feb 22 15:45:58 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968815, encodeId=b34c196881590, content=<a href='/topic/show?id=6e2d42514f8' target=_blank style='color:#2F92EE;'>#复发型多发性硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42514, encryptionId=6e2d42514f8, topicName=复发型多发性硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Nov 01 00:45:58 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353493, encodeId=0fbb1353493ed, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71883, encryptionId=43abe1883b6, topicName=百时美施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 28 11:45:58 CST 2020, time=2020-03-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1983107, encodeId=31d4198310e19, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jul 29 11:45:58 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839785, encodeId=c68e1839e85bf, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Jul 06 23:45:58 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890104, encodeId=823d18901048b, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Mar 09 06:45:58 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764466, encodeId=52fb1e64466a2, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71882, encryptionId=8fe0e188265, topicName=百时美)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b037737594, createdName=ms1467340776200723, createdTime=Sun May 17 02:45:58 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685291, encodeId=c38416852913d, content=<a href='/topic/show?id=03135881224' target=_blank style='color:#2F92EE;'>#施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58812, encryptionId=03135881224, topicName=施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=394828104279, createdName=jktdtl, createdTime=Mon Feb 22 15:45:58 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968815, encodeId=b34c196881590, content=<a href='/topic/show?id=6e2d42514f8' target=_blank style='color:#2F92EE;'>#复发型多发性硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42514, encryptionId=6e2d42514f8, topicName=复发型多发性硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Nov 01 00:45:58 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353493, encodeId=0fbb1353493ed, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71883, encryptionId=43abe1883b6, topicName=百时美施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 28 11:45:58 CST 2020, time=2020-03-28, status=1, ipAttribution=)]

相关资讯

FDA拒绝了Celgene旗下的Ozanimod用于多发性硬化症

Celgene周二(2018年2月27日)宣布,它已收到FDA拒绝关于该公司在治疗复发型多发性硬化症患者中使用Ozanimod的市场推广申请的信函。Celgene解释说,经过初步审查,FDA认为Celgene提交的非临床和临床药理学部分不足以进行全面审查。Celgene首席医疗官Jay Backstrom评论说:“我们将继续与FDA合作,尽快解决所有未解决的问题,并将这种重要药物带给患者。”

2019年欧洲神经病学学会EAN:Ozanimod显着减少复发多发性硬化患者的脑容量损失

第5届欧洲神经病学学会(EAN)上的最新报告,与干扰素β-1a相比,Ozanimod在复发性多发性硬化症(MS)患者中更好地减少了全脑容量、皮质灰质体积和丘脑体积的损失。

NEJM:ozanimod治疗溃疡性结肠炎初见成效

Ozanimod(RPC1063)是鞘氨醇-1-磷酸受体亚型1和5的口服激动剂,可诱导外周血淋巴细胞隔离,有可能减少活化的淋巴细胞循环到胃肠道的数量。原始出处:William J. Sandborn,Brian G. Feagan,Douglas C. Wolf,et al.Ozanimod Induction and Maintenance Treatment for Ulcerative Co

Baidu
map
Baidu
map
Baidu
map